Registration is now open for the 2017 Vascular Annual Meeting, scheduled for 31 May–3 June in San Diego, USA. Plenaries and exhibits open on 1 June.
Alvimedica’s Illumina study enrolment is now complete. The Illumina study has been designed to evaluate the efficacy and safety of the new NiTiDES self-expanding polymer free drug-eluting stent for the superficial femoral artery, manufactured by CID SpA, a member of Alvimedica group. Currently this device represents the first attempt to embed a controlled and targeted drug elution (two to three months) with a polymer-free nitinol platform.
North Dallas Research Associates, Dallas, Texas, and its private practice, Cardiac Center of Texas, have announced their participation in the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial.
The US Centers for Medicare & Medicaid Services (CMS) have released the proposed decision memo for the approval of supervised exercise therapy for the treatment of peripheral artery disease (PAD). This was triggered by the receipt last year of a request from the American Heart Association to initiate a national coverage analysis in order to establish a national coverage determination for said exercise therapy programmes.
Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease.
Changes in tiny blood vessels of the eye may predict a higher risk of later narrowing in the large blood vessels in the legs, according to a study presented at the American Heart Association’s Epidemiology and Prevention Lifestyle and Cardiometabolic Health 2017 Scientific Sessions.
AV Medical Technologies has announced that its Chameleon PTA balloon catheter has received FDA clearance for an expanded indication to include infusion of diagnostic or therapeutic fluids.
PQ Bypass has announced CE mark approval for a trio of proprietary devices: the Torus stent graft system, PQ Snare, and PQ Crossing Device, which enables physicians to perform a fully percutaneous femoropopliteal bypass in patients with TASC II C and D lesions in the superficial femoral artery due to peripheral artery disease (PAD).
Even after adjusting for differences in age and comorbidities, female patients have higher perioperative mortality and lower long-term survival after thoracic endovascular aneurysm repair (TEVAR), according to a study published by the Journal of Vascular Surgery.
BrightWater Medical has announced that the US FDA has cleared the company’s innovative ConvertX nephroureteral stent system for treatment of ureteral obstructions.
“There is no easy fix with current endovascular tools and strategies and a default realisation is that it is easier and more definitive to treat aortic dissection early,” Michael D Dake, Stanford, USA, told Interventional News about the Achilles heel of thoracic endovascular aneurysm repair (TEVAR) management for uncomplicated type B dissection.
Selective internal radiation therapy (SIRT) has been available since December 2013 to a defined group of patients with liver metastases in England on the National Health Service (NHS) via a special Commissioning through Evaluation scheme from NHS England. However, NHS England has now decided to stop funding SIRT at the end of March 2017 while it analyses the data obtained so far.
Spectranetics has announced that its Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark. The device is designed to treat small vessels, below-the knee disease, and challenging critical limb ischemia in patients.
Cook Medical has completed enrolment in the first clinical study of an iliofemoral venous stent conducted in the USA under a US FDA-approved investigational device exemption.
Ulipristal acetate is the first oral therapy to demonstrate efficacy and safety for uterine fibroids in two US pivotal studies, a press release states.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos